CN104012838B - 非变应原性的成分和食品 - Google Patents
非变应原性的成分和食品 Download PDFInfo
- Publication number
- CN104012838B CN104012838B CN201410047278.4A CN201410047278A CN104012838B CN 104012838 B CN104012838 B CN 104012838B CN 201410047278 A CN201410047278 A CN 201410047278A CN 104012838 B CN104012838 B CN 104012838B
- Authority
- CN
- China
- Prior art keywords
- food
- composition
- weight
- acid
- food according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 116
- 235000013305 food Nutrition 0.000 title claims abstract description 105
- 150000002632 lipids Chemical class 0.000 claims abstract description 61
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 41
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 40
- 150000001413 amino acids Chemical class 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 23
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 21
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 21
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 20
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 20
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 19
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 16
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 41
- 229920001542 oligosaccharide Polymers 0.000 claims description 41
- 206010020751 Hypersensitivity Diseases 0.000 claims description 38
- 239000000463 material Substances 0.000 claims description 38
- 235000014633 carbohydrates Nutrition 0.000 claims description 36
- 230000007815 allergy Effects 0.000 claims description 35
- 235000001014 amino acid Nutrition 0.000 claims description 35
- 150000001720 carbohydrates Chemical class 0.000 claims description 35
- 208000026935 allergic disease Diseases 0.000 claims description 33
- 150000002482 oligosaccharides Chemical class 0.000 claims description 32
- 239000013566 allergen Substances 0.000 claims description 26
- 235000018102 proteins Nutrition 0.000 claims description 18
- 241000894006 Bacteria Species 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 13
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 235000008521 threonine Nutrition 0.000 claims description 7
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 6
- 229940106189 ceramide Drugs 0.000 claims description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 241000186660 Lactobacillus Species 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000020778 linoleic acid Nutrition 0.000 claims description 4
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 4
- 241000186000 Bifidobacterium Species 0.000 claims description 3
- 206010012444 Dermatitis diaper Diseases 0.000 claims description 3
- 208000003105 Diaper Rash Diseases 0.000 claims description 3
- 210000002421 cell wall Anatomy 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 3
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 3
- 150000002270 gangliosides Chemical class 0.000 claims description 3
- 229940039696 lactobacillus Drugs 0.000 claims description 3
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 2
- 150000003588 threonines Chemical class 0.000 claims description 2
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 2
- 238000006384 oligomerization reaction Methods 0.000 claims 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 150000001721 carbon Chemical class 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 239000000047 product Substances 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 23
- 108090000790 Enzymes Proteins 0.000 description 19
- 102000004190 Enzymes Human genes 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 19
- 235000013350 formula milk Nutrition 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 12
- 239000005017 polysaccharide Substances 0.000 description 12
- 150000003626 triacylglycerols Chemical class 0.000 description 12
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- -1 sulfatide Chemical class 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 6
- 230000000172 allergic effect Effects 0.000 description 6
- 230000000774 hypoallergenic effect Effects 0.000 description 6
- 150000007524 organic acids Chemical class 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 208000010668 atopic eczema Diseases 0.000 description 5
- 230000002349 favourable effect Effects 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 208000003455 anaphylaxis Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 239000013568 food allergen Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000001471 micro-filtration Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010002199 Anaphylactic shock Diseases 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 3
- 150000003271 galactooligosaccharides Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 210000001630 jejunum Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical group CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 2
- FPRKGXIOSIUDSE-SYACGTDESA-N (2z,4z,6z,8z)-docosa-2,4,6,8-tetraenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C(O)=O FPRKGXIOSIUDSE-SYACGTDESA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDYAPQVYJXUQNY-OPHDRXFHSA-N 1,2-di-(alpha-linolenoyl)-3-[alpha-D-galactosyl-(1->6)-beta-D-galactosyl]-sn-glycerol Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](OC[C@@H](COC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC)O[C@@H]1CO[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KDYAPQVYJXUQNY-OPHDRXFHSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 235000017060 Arachis glabrata Nutrition 0.000 description 2
- 244000105624 Arachis hypogaea Species 0.000 description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 description 2
- 235000018262 Arachis monticola Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 235000016068 Berberis vulgaris Nutrition 0.000 description 2
- 241000335053 Beta vulgaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000015943 Coeliac disease Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 229920002488 Hemicellulose Polymers 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 102000008070 Interferon-gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 102000001621 Mucoproteins Human genes 0.000 description 2
- 108010093825 Mucoproteins Proteins 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010049416 Short-bowel syndrome Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 210000004241 Th2 cell Anatomy 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 230000037058 blood plasma level Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000001982 diacylglycerols Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000000105 enteric nervous system Anatomy 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 235000012041 food component Nutrition 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000002298 globosides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 235000020232 peanut Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- JCZPMGDSEAFWDY-SQOUGZDYSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanamide Chemical compound NC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO JCZPMGDSEAFWDY-SQOUGZDYSA-N 0.000 description 1
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- YUFFSWGQGVEMMI-UHFFFAOYSA-N (7Z,10Z,13Z,16Z,19Z)-7,10,13,16,19-docosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCCC(O)=O YUFFSWGQGVEMMI-UHFFFAOYSA-N 0.000 description 1
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 description 1
- 102400000739 Corticotropin Human genes 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000015510 Cucumis melo subsp melo Nutrition 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010068370 Glutens Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000235575 Mortierella Species 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000233639 Pythium Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001877 deodorizing effect Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- XIVFQYWMMJWUCD-UHFFFAOYSA-N dihydrophaseic acid Natural products C1C(O)CC2(C)OCC1(C)C2(O)C=CC(C)=CC(O)=O XIVFQYWMMJWUCD-UHFFFAOYSA-N 0.000 description 1
- 108700003601 dimethylglycine Proteins 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000020215 hypoallergenic milk formula Nutrition 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 235000021290 n-3 DPA Nutrition 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000007065 protein hydrolysis Effects 0.000 description 1
- 235000021251 pulses Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical class O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CMXPERZAMAQXSF-UHFFFAOYSA-M sodium;1,4-bis(2-ethylhexoxy)-1,4-dioxobutane-2-sulfonate;1,8-dihydroxyanthracene-9,10-dione Chemical compound [Na+].O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O.CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC CMXPERZAMAQXSF-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 150000003544 thiamines Chemical group 0.000 description 1
- 235000021404 traditional food Nutrition 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000003519 ventilatory effect Effects 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
- A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
- A23D9/013—Other fatty acid esters, e.g. phosphatides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11C—FATTY ACIDS FROM FATS, OILS OR WAXES; CANDLES; FATS, OILS OR FATTY ACIDS BY CHEMICAL MODIFICATION OF FATS, OILS, OR FATTY ACIDS OBTAINED THEREFROM
- C11C1/00—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids
- C11C1/02—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils
- C11C1/04—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by hydrolysis
- C11C1/045—Preparation of fatty acids from fats, fatty oils, or waxes; Refining the fatty acids from fats or fatty oils by hydrolysis using enzymes or microorganisms, living or dead
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
本发明涉及非变应原性食品,其包括:‑氨基酸组分,其包含选自由氨基酸和聚合度为7以下的肽组成的组的至少一种成分;和‑脂质组分,其包含选自由花生四烯酸和二十二碳六烯酸组成的组的至少一种脂肪酸,所述组合物具有一定含量的具有1000道尔顿以上的分子量的蛋白质和其它肽,所述含量为基于干重,少于0.01重量%,优选地少于0.001重量%,更优选地少于0.0001重量%。
Description
本申请是申请日为2007年8月3日的中国专利申请200780036351.6的分案申请。
本发明涉及易于消化的食品,非变应原性的食品,制备所述产品的方法,治疗具有变态反应的人的方法,在具有变态反应的人中诊断食品变态反应的方法以及适合作为本发明所述的食品的成分的组合物。
食品变态反应是常见并且在逐渐增多的问题。其本身可以在生命早期,婴儿阶段就有表现。特别是具有所谓的特应性体质的那些人可能发展对各种蛋白质的变态反应,所述蛋白质如来自牛奶、大豆、鸡蛋、花生或小麦(谷蛋白)的那些。通常这些变态反应在数月到数年后消失。在生命后期,可能发展新的变态反应,如来自尘螨、花粉的那些或来自花的其它蛋白质或来自果实的成分。
患有变态反应的人可能难以消化或代谢某些食物成分,这可能导致不需要的副作用以及对所述成分的不耐受。乳糖不耐受是其常见的实例,因为该原因,经常将乳糖从低变应性营养配方中除去。
具有变态反应的人可能发展胃肠问题,如果在他们的饮食中存在所述成分的话,这可能会进一步使所述个体的疾病恶化。
在具有变态反应的人中,强烈的全身反应典型地在暴露于变应原后发展。这可以在暴露后立即导致许多症状,并且可以在暴露后以后,例如在1或2天后发展。认为这些反应是由变应原与朗格汉斯型细胞或树突细胞、调节T细胞以及与Toll样受体(TLR)例如在肠道相关性淋巴组织(GALT)细胞中的TLR-4相互作用介导的。通过激活多种淋巴细胞、嗜曙红细胞、肥大细胞和嗜碱性细胞特异性释放免疫球蛋白(Ig)、蛋白酶、组胺和细胞因子、前列腺素(PG)、白三烯、羟基二十碳四烯酸、白介素(IL)和其它信号传导化合物,产生了针对所述变应原的反应。认为特别是由B细胞释放的IgE具有重要的作用。人发展变态反应的体质似乎与1型和2型T辅助细胞的数量以及调节T细胞的数量相关。认为特别是Th1与Th2细胞数量的较低比率,以及在Th2与调节细胞的数量的比率的GALT中的异常值反映了发展变态反应的增加的风险。典型地,在健康非变应性的婴儿中,这样的比率在出生后很短的时间内相对较低并且在随后的前几周内迅速增加。
可以作为变态反应的结果观察的症状包括皮肤的反应(刺激,局部炎症),产生粘液的组织如在鼻、嘴、消化道上皮、肺和喉咙中的组织的反应(过敏性鼻炎,刺激,喷嚏,肿胀),眼睛的反应(眼泪),呼吸系统的反应(哮喘,呼吸阻塞(ventilatory obstruction)),胃肠道反应(腹泻、消化道内的局部炎症反应或在较长距离的炎症反应),全身反应(如例如表现为组胺的血浆水平增加和如果存在干扰素-γ,较低水平)和行为问题(易怒,婴儿的哭闹时期)。
婴幼儿的特应性皮肤反应还经常导致儿童臀部的炎症反应(尿布疹)。炎症还可能在具有变态反应的成人中发生,例如如果他们搔抓瘙痒区域太多次的话。
所述变态反应还可能导致疼痛、瘙痒感觉、以及身体性能的降低和身体的疾病。在患有变应性哮喘或变应性支气管炎的人中,导致呼吸短促。其还可能妨碍睡眠模式或阻碍生命的正常功能。其甚至可能引起具有严重临床影响的问题,如导致休克,特别是过敏性休克。
当将未达到足够纯度的药物应用于治疗具有特应性或变应性体质的人时,并且特别是当所述药物通过肠胃外途径施用时,过敏性休克或另一种形式的过敏反应也可能发生。已知有被痕量的变应原污染的风险的所述药物的实例是抗生素,局部麻醉剂,可待因,由动物制备的药物或通过使用外源蛋白如酶如胰岛素、促肾上腺皮质激素制备的药物,象这样的酶,诊断剂如用于MRI或X-射线的造影剂,疫苗,抗毒素,γ-球蛋白,干扰素等。当处于发展所述变态反应危险中的人暴露于植物或动物毒液,例如昆虫如蜜蜂、黄蜂或胡蜂的毒液时,也可能发生所述过敏性休克。
诊断食物的变态反应是麻烦的任务,尤其在幼儿中诊断更是如此。因为传统的变态反应皮肤测试被认为对婴儿是相当具有侵入性的,因此经常使用其它方法如检验性和误差性实验,其使用常规饮食成分或使用较低变应性的合成食物(“低变应原性”食物)进行。延迟反应的可能发生使结果的解释变得十分困难。此外,低变应性食物仍可能导致变应原性反应。食品法限定了低变应原性配方必需符合的标准。在本文中,如果在豚鼠中的激发测试中,食物的变应原性比所述成分从其中制备的原始物质的变应原性低至少1000倍,那么所述食物被认为是低变应原性的。
所述低变应原性食品的实例是Neocate。其包括氨基酸(特别是色氨酸,苏氨酸,精氨酸和甲硫氨酸)。所述产品不包括纤维,也不包括长链多不饱和脂肪酸(缩写为LCP’s)。
存在对于非变应原性食品的需要,特别是用于未成年人(infant)的食品,更特别地用于具有特应性体质的未成年人的食品。
提供这样的非变应原性食品是合乎需要的,所述食品给受试者提供令人满意的营养品,其符合所述受试者的所有的营养需求并且所述产品是适口的和/或方便使用的。
此外,提供适合用于确定变态反应的诊断方法的食物也是需要的。
提供这样的食品是合乎需要的,所述食品能够改善暴露于(少量变应原)的受试者的变态反应,例如当用包含少量变应原的食品养育或当暴露于可能包括痕量变应原的药物时。
在特定的未成年人组的胃肠道中,有一些疾病较为普遍,其增加了对于变应原的敏感性并且促进对于食品成分的不耐受。例如不足月的婴儿(infants of younggestational age)通常消化食品成分的能力不足,并且释放异常量的胃肠激素和酶。其产生免疫功能并且特别是针对潜在变应原的反应。乳糜泄(coeliac)患者不能完全消化谷蛋白和肽。患有短肠综合征和腹泻的人经历增加的通过时间,这使得其不能正确的消化并且吸收消化的成分。患有胃肠道上皮细胞炎症的人如患有局限性回肠炎和其它炎性肠病的那些人,和经历长期药物应用如非类固醇抗炎剂的那些人,对消化和吸收食物成分的能力降低。
此外,暴露于特定药物组治疗的患者,特别是未成年人,发展了增加的敏感性从而产生了暴露于潜在的变应原的变态反应,所述药物如抗生素或化疗剂。患有囊性纤维化的患者还显示了在长距离的消化道中增加水平的更大的肽,释放由胃肠道产生的激素和酶的不正常的模式以及发展变态反应的增加的危险。
尽管对为这些特定组的受试者,尤其是儿童正确提供食物付出了巨大的努力,他们中的许多人还是营养不良。这些特定组的疾病状态也要求采取所有可能的预防措施来避免发展对施用的食品的变态反应。
因此,存在对于这样食品的需要,所述食品能够适当地滋养营养不良的人或患病的人的特定群体,并且同时防止这些患者在暴露于潜在的变应原后发展变态反应。
本发明的目的是提供新的食品,特别是非变应性的食品,其满足在本发明说明书和/或权利要求中鉴定的一种或多种需要、需求和/或作用。
现在,通过提供具有特定氨基酸组分、特定脂质组分和任选地特定碳水化合物组分的食品来实现所述目标已经是可能的。
因此,本发明涉及这样的食品,其包括:
-氨基酸组分,所述氨基酸组分包括选自由游离氨基酸、包括其盐、和具有7以下的聚合度的肽组成的组的至少一种成分;
-脂质组分,所述脂质组分包括选自由花生四烯酸(AA)和二十二碳六烯酸(DHA)组成的组的至少一种脂质;和任选地
-不易消化(non-digestible)的碳水化合物组分,其包括基于碳水化合物组分重量至少80重量%的寡糖,所述寡糖具有3-20范围内的聚合度,
所述组合物具有一定含量的肽物质(氨基酸和肽,包括蛋白质),所述肽物质具有1000道尔顿以上的分子量,所述含量基于干重少于0.01重量%,优选地少于0.001重量%,更优选地少于0.0001重量%和最优选地少于0.00001重量%,或甚至低于检测水平,或完全缺乏。
所述食物基本无变应原性。
术语“无变应原性”在本文中定义为具有这样含量的具有1000道尔顿以上的分子量的肽物质,所述含量为少于0.01重量%,尤其是少于0.001重量%,更特别地少于0.0001重量%,和甚至更特别地少于0.00001重量%,或甚至低于检测水平,或完全缺乏。
“即用(ready to use)”液体产品可以适当地从例如25g本发明的固体产品/100ml的适合的液体,如水制备,但实际上可以使用不同的固体与液体比率。当在本文中以重量/体积单位或摩尔/体积单位提及产品的成分浓度时,通常是指本发明的“即用”液体产品的浓度。典型地,所述提及的浓度基于具有25g干重的产品/100ml的浓度。因此,一般而言,基于干重的浓度是提及的重量/100ml的浓度的四倍,除非另外指出。
优选地,本发明的无变应原性食品基于干重,具有少于0.01重量%,更优选地少于0.001重量%的T细胞表位含量。
如果当地法律要求明确公开成分的详细性质,那么肽物质的分子量可以从商购食品成分的标签上读取,或优选地所述肽物质的分子量通过分离肽物质并且随后分析其分子大小来确定。分离可以基于在本领域中已知的方法如提取、过滤和层析来从营养品中存在的其它成分中纯化和分开来进行。可以通过利用层析法或电泳技术的分离和随后的分析例如通过分光光度法来进行量化。
本发明的食品的无变应原特征还容许将这样的食品用作(完全的)营养品提供给变应性的人,特别是未成年人(infant)(7岁以下),或甚至是婴儿。
在测试受试者的变应性的阶段中,所述食品还适合作为营养品提供给人,包括未成年人,特别是婴儿。有利的是,可以使用本发明的食品,而不具有干扰所述测试的较大危险,原因在于使用本发明的食品时可以不存在由食品的成分导致的变应原反应的较大风险。
本发明人还预期本发明的食品实际上可以减少对不存在于所述食品中的变应原的变态反应。不受限于任何理论,由于存在特定非变应性脂质(AA和/或DHA)和任选地特定的非变应性不易消化的碳水化合物组分,假设所述食品可以对在暴露于一定量的特定变应原后释放的Th1/Th2比率和IgE的量具有正向影响。
一般而言,所述氨基酸组分、脂质组分和碳水化合物组分以这样的量存在从而使氨基酸组分提供约8到约15.7能量%,脂质组分提供约38-约52能量%并且碳水化合物提供约38到约47能量%。这些量基于下列能量组成:关于蛋白质、肽、氨基酸、有机酸和可消化碳水化合物为16.8kJ/g,以及每克脂质37.8kJ。其它成分如纤维(难以消化(indigestible)的碳水化合物)、矿物质、维生素和核苷酸或其等价物不提供能量。
根据本发明的即用营养产品的能量密度是每毫升约2.52到约3.24,优选地约2.6到约3.1千焦(或每100g干重约10.04-约12.96千焦,分别地每100g干重约10.04-约12.4千焦),特别使其非常适合施用于变应性的未成年人。
氨基酸组分是游离形式的氨基酸(包括其盐及酯)、和以肽(包括蛋白质,糖蛋白和脂蛋白)的形式存在的氨基酸的总和。其提供氨基酸来源,从所述氨基酸来源身体可以合成蛋白质和其它肽。一般而言,基于所述产品的总干重,具有8以上的聚合度(DP)的肽(包括蛋白质)的量少于0.01重量%。根据所述产品的无变应原特征,优选具有8以上DP的肽的量是少于0.001重量%。
优选地,存在精氨酸。通过使用氨基酸组分获得最佳结果,其包含约1.0到约7.1克精氨酸/100g氨基酸。然而,优选地,所述精氨酸含量相对较低,特别地在每100g氨基酸组分约1.0到约6.9克的范围内或甚至更好地在约1.5到约6.0克精氨酸范围内,从而改善变态反应。
优选地存在苏氨酸,因为苏氨酸可以增加消化道中粘蛋白的产生,所述粘蛋白减少暴露于上皮细胞的变应原,容许更好地消化食品变应原并且增加变应原的消除。关于针对已被食用的食品变应原的相对较慢的反应,苏氨酸被认为是特别有效的。苏氨酸含量可以是每100g氨基酸组分约5.0到约13克,但是优选地在约5.5到约11克苏氨酸的范围内。
优选地存在色氨酸,因为其可以增加Th1/Th2比率,或其可以减少Th2/调节T细胞比率,所述效果减少对潜在变应原的反应。对于在暴露后立即的或延迟的反应,或两种类型的反应,其可以是有效的。色氨酸含量在每100g氨基酸级分约2.0到约7.0克的范围内,但是优选地约2.2到约6.0克色氨酸范围内。
优选地包含天冬酰胺和/或天冬氨酸以支持免疫系统,其浓度为每100克氨基酸包含约6.4到约15克,优选地约8到约13克,更优选地约9到约12克天冬氨酸等价物(天冬酰胺和天冬氨酸的总和)。
氨基酸组分优选地包含所有的必需氨基酸。
倾向用于PKU患者的食品典型的不含苯丙氨酸。
脂质组分是所述产品中的脂质的总和。具体而言,所述脂质组分可以包括至少一种脂质,特别是至少两种脂质,更具体而言至少三种脂质,所述脂质选自由下列各项组成的组:甘油三酯、二酰甘油酯(diacylglyerides),单酰甘油酯(mono-acylglycerides),磷脂,溶血磷脂,神经酰胺,鞘氨醇,神经节苷酯,红细胞糖苷酯,硫苷脂,类固醇酯,游离脂肪酸,游离脂肪酸的盐和游离脂肪酸的酯。优选地,至少80重量%的脂质组分由一种或优选地至少两种或至少三种该组脂质形成。
如上所示,脂质组分包括选自花生四烯酸(AA)和二十二碳六烯酸(DHA)的至少一种脂质。AA和/或DHA可以以游离脂肪酸、游离脂肪酸的盐、游离脂肪酸的酯(例如,作为甘油酯)、作为酰胺、或以适合在食品中使用的另一种形式存在。
本发明人已经认识到AA存在的有益方面是其在身体的前列腺素、特别是PgE2产生中的作用。本发明人预期,即使通常认为前列腺素增加变应性反应,这种产生有利于利用所述产品养育的受试者。
本发明人已得出结论,即DHA可以有助于减少作为变应性反应的结果的炎性反应,特别是作为继发性并发症的局部炎性反应,例如作为过分搔抓的结果或作为腹泻的结果的局部炎性反应。
还预期饮食来源的DHA改善了参与免疫应答的细胞的膜组成。这导致潜在变应原的更特异性的识别模式,并且在激活参与变态反应的受体如那些细胞因子后改变信号传导途径,并且因此改变了对暴露于潜在变应原的反应。
还预期AA、DHA或两者的存在可以是有利的,因为这些改变了中枢神经系统和/或肠神经系统对外源肽物质存在的反应的方式。特别地,这些成分可以抑制肠神经系统对潜在食物变应原在胃肠道中的存在的反应,和特别地对抗原呈递细胞的反应。认为这可能是对参与免疫应答的神经细胞和树突细胞以及其他细胞的膜的结构和功能的有利作用的结果。
还预期该AA、DHA或两者可有利于减少或避免抑郁的感觉,所述感觉可能不利地影响变应原性反应。
AA含量优选地是至少0.25g/100g脂肪酸(包括以结合形式存在的脂肪酸诸如以酯(包括甘油酯)、酰胺或盐存在)。所述含量可以是高到约6g/100g脂肪酸,但是优选地在脂质组分中的浓度在约0.4到约0.8g花生四烯酸/100g脂肪酸的范围内。
所述DHA含量优选地是至少0.15g/100g脂肪酸。所述含量可以是高到约1.5g/100g脂肪酸,但是优选地所述浓度在约0.16到约0.8g DHA/100g脂肪酸的范围内。
优选地AA与DHA的重量比率是约1-5:1。
优选地包括一种或多种n-3脂肪酸。认为它的存在是有利的,从而防止或至少减少二十二碳四烯酸在细胞特别是神经细胞和/或视网膜细胞的膜中的积累。除此之外,DHA优选的n-3脂肪酸的实例包括α-亚麻酸(ALA),二十碳五烯酸(EPA)二十二碳五烯酸(DPA3)。
为了防止二十二碳四烯酸的积累,亚油酸(LA)与DPA和DHA和EPA的总和的比率可以是约10-60:1,但是优选地更低,特别是约0-47:1或甚至更好地约10-40:1。
脂质组分优选地不包含浓度超过0.01重量%的分子量在1000道尔顿以上的肽物质,如例如脂蛋白的蛋白质部分,并且优选地包括少于0.001重量%的所述物质。
根据本发明的脂质可以从包含所述肽能物质的天然物质中分离,诸如来自动物、植物、真菌或细菌来源的组织。来自动物起源的脂质的实例是奶,卵或脑,或鱼。植物性脂质特别是那些从包括超过1%DHA或AA的种子或豆类植物(pulses)中分离的那些脂质。真菌来源的脂质的实例是从被包霉(Mortierella)或腐霉(Pythium)物种或从改良的酵母中分离的那些油。
蛋白质物质可以通过对被选择的原料特异的方法去除。一些纯化原料油和脂质的通用方法是本领域已知的,如酸处理(其还去除树胶),漂白(bleaching)或用吸附剂如硅酸盐处理,过滤技术,结晶或冷却和除臭方法。这些可以适合于纯化本发明所述的脂质。
然而,根据本发明的脂质可以仅通过改变一个或多个这些工艺步骤或另外应用一个或多个步骤来去除或破坏残余的肽物质来符合所述规格,所述残余的肽物质包括脂蛋白和处理辅助剂如酶。所述另外的步骤可以是例如在升高的温度(>50℃)吸附到色谱柱上或适合的过滤床上。
改进方法的另一个实例是应用微量过滤或超滤。一旦已经通过以传统方法(使用大孔滤器或助滤剂)进行过滤或通过离心过滤进行了预过滤,所述方法就可以成功地应用。用于微量过滤的适合的孔的大小低于5微米并且优选地最终滤器的孔的大小是0.01-1μm。
此外,在过滤或吸附之前,可以将这样的成分加入不纯的脂质组分中,所述成分附着于肽物质以增加对柱的吸附。还可以加入这样的物质以在冷滤或冷却过程中增加蛋白质的絮凝速率或增加过滤功效。所述成分优选地是食品级别的物质如两性物质如胆碱、甜菜碱、二甲基甘氨酸、或选自钙和镁组的一种或多种矿物质。
神经酰胺,鞘氨醇,硫苷脂,红细胞糖苷酯和其他糖苷化的脂质需要合适的方法来使这些极性更强的脂质与所述肽物质分离。具体而言,层析方法如应用离子交换,特别是阴离子交换的那些似乎是有用的。
合成物质如一些二酰甘油酯或单酰甘油酯和溶血磷脂通常使用脂肪酶或磷脂酶生产。这些酶的性质决定应用修饰的或另外的步骤。例如,球形酶的变性使在沉淀和过滤或离心前的热处理变得有吸引力。过滤可以以一个或多个步骤发生。优选地,粗滤或离心与在升高温度的微量过滤步骤组合。
变性这些脂肪酶的适合的加热温度是超过80℃和优选地约85°到约110℃。
优选采用所述脂质来源从而改变在脂质产品中和在消化道中的胶束形成,并且因此改善消化特征。这通过在所述产品中包含相对低量的甘油三酯实现。在为营养不良的未成年人或不能食用正常量的液体配方而开出的常规的未成年人配方中,甘油三酯的水平可以等同于每100ml即用配方多达7.0g的水平(或达到干重的28.0重量%)。优选应用下列两种方法之一从而减少甘油三酯的量。第一种方法意味着减少到低于4.0g/100ml的值(或低于干重的16.0重量%),优选地在约2.9到约3.9g/100ml即用配方(或干重的约11.6到约15.6重量%)范围内。最优选地,甘油三酯的量等同于约3.0到约3.7克/100ml(或干重的约12.0到约14.8重量%)。
在第二种方法中,至少部分甘油三酯被备选脂质组的一个或多个成员所取代,所述备选组由甘油单酯、甘油二酯、磷脂、神经节苷脂、溶血磷脂、神经酰胺、鞘氨醇、修饰的神经酰胺(硫苷脂等)和胆固醇酯组成。在所述配方中的脂质含量越高,则越多的甘油三酯必须被取代。当乳状液被适当地配制并且特别是给出这样的小滴时,发现大多数未成年人可以适当地消化约3.4克量的甘油三酯,所述小滴具有5微米以下的平均粒度[dp(3,4)]和优选地对于重构的干产品0.1-3微米的平均粒度和对于即用液体产品0.1-0.3微米的平均粒度。鉴于总脂质组分和3.4g甘油三酯之间的差异,优选用备选脂质替换脂质组分的其余部分。具体而言,在具有2.9-3.9g/100ml即用配方的甘油三酯含量的营养产品中,尤其有利的是包含约0.5到约4重量%,优选地约0.7到约3重量%的脂质组分作为磷脂,并包括约0.4到约1.4重量%的胆固醇或其等价物,如胆固醇酯。包含所述备选脂质的营养产品形成易于消化的乳状液。认为这特别是由于通过胰凝乳蛋白酶进行的提高的蛋白质水解所导致的。此外,认为消化得到的产物与常规配方的那些不同,并且结果是容纳所述产物的消化道上部、特别是空肠和回肠的内腔的内容物,不同地呈递到胃肠道中的树突细胞和Toll样受体,特别是存在于GALT中的TLR-4。
这种在呈递上的差异还将涉及细菌、细菌产物和细菌细胞壁的片段。当脂质包括超过0.1重量%的胆固醇或其等价物时,在所述配方中包含细菌细胞壁的片段将是有益的,所述细菌特别是那些在消化道上部共生的细菌,如乳杆菌(Lactobacilli)和双歧杆菌属(Bifidobacteriae)。有益的量是每100ml即用产品108到1011个细菌,或约0.02-0.4g富含片段的物质(或基于干重:每100g产品4x108到4x1011个细菌,或约0.08-1.6重量%的富含片段的物质)。后一种物质可以包含核苷酸。
不易消化的碳水化合物组分是在所述产品中不易消化的碳水化合物的总量。
不易消化性可以通过应用Lee等,J Assoc Off Anal Chem,75,395-416,1992的方法确定。如果所述碳水化合物可消化50%以上,认为所述碳水化合物的总量是可消化的。
本领域已知将不易消化的碳水化合物(膳食纤维)包含在食品中。在本领域中,一般认为较大的碳水化合物(多糖)是合乎需要的。本发明人得出这样的结论,即,在解决本发明待解决的问题方面,如改善变态反应上,较小的难以消化的碳水化合物是出人意料地有效的。
预期在本发明的产品中的具有多达20的DP的难以消化的寡糖对Th1/Th2比率具有正向作用。
此外,本发明人已经意识到,在所述食物的质地和/或处理性质上,特别是将作为液体被食用的食物方面,较小的碳水化合物的存在(DP达到20)是有利的。在溶液中,寡糖通常在基本是不具有粘性的,或对粘性仅有微小的作用。特别地,在20℃的温度下,在100/秒的剪切速率,在水中2重量%的溶液导致100mPa.s以下的粘度。因此,所述寡糖可以用在产品中,从而提供具有100m Pa.s以下,特别是50m Pa.s以下,优选地20m Pa.s以下的粘度的产品。在易于施用(例如易于饮用)和/或所述产品的质地/口感方面,发现这是有利的。
优选地,所述产品包括至少一种选自由下列各项组成的组的寡糖:
半乳糖-寡糖,果糖-寡糖,木糖-寡糖,甘露糖-寡糖,半乳糖醛酸-寡糖和阿拉伯糖-寡糖。当由该寡糖水解产生的超过90%的单糖属于这一种类型时,这些寡糖被分类为属于一组单糖(例如,半乳糖-寡糖)。在该文件中,它们被称为单-寡糖。混合类型的寡糖包括两种类型以上的单糖,其中每种类型提供该寡糖的超过10%的重量。
更优选地,包含两种以上的单-寡糖,其在产生丁酸、丙酸、乙酸和乳酸方面,在酸化动力和在形成气体如氢气或甲烷方面,具有不同的发酵模式。这些发酵模式通过使用这样的微生物来确定,所述微生物在胃肠道的第一部分共生,即在口、喉、食管、胃、空肠和回肠的最初25%的部分中的那些。特别地,在口和在空肠/回肠中存在的那些似乎在影响与潜在变应原的反应中很重要。
实际上,在产生足量的丁酸和尤其是与乙酸相当的乳酸方面和/或支持多种这些天然存在的共生体方面,三种以上的单-寡糖似乎是最有利的。特别地,半乳糖-寡糖、糖醛酸-寡糖和木糖-寡糖的混合物是有利的,例如1:0.2-5:0.2-5比率的半乳糖寡糖,果胶水解产物和木糖-寡糖的混合物。
这些单-寡糖混合物的有利之处在于每种成分包含少量的肽能物质,如酶和从起始物质如牛奶蛋白来源的残余蛋白。
因此,关于至少等同的结果,备选地可以包含混合类型的寡糖,其仅需要一个纯化步骤来去除潜在的变应性肽能物质。特别地,当以超过15重量%、或甚至更优选地超过20重量%的量包含至少两种单糖时,混合类型的寡糖是适合的。
混合类型的寡糖可以通过使选择的单糖彼此反应来获得具有需要的链长度或化学结构的寡糖进行合成,或可以通过水解混合类型的多糖来获得。这些多糖优选地是天然来源的。适合的混合类型的寡糖还可以通过将多糖的混合物水解为小的寡糖,随后将其彼此结合(attach)来获得。适合的多糖的实例是纤维素、半纤维素和果胶等的混合物,如在豌豆纤维或各种糠(水稻,玉米,大麦)或甜菜纤维中存在的那些。此外,多糖的人工混合物可以通过将选择量的适合的多糖如半纤维素、纤维素、β-葡聚糖、藻多糖、果聚糖、树胶(如瓜尔胶或刺槐豆胶或阿拉伯树胶)和粘质混合进行制备。在水解并产生需要的单糖和寡糖后,终止反应并将反应产物分离和应用,或进行新的酶促步骤,其中将单个的单糖或寡糖彼此结合从而产生新的混合的寡糖。合成所述混合的寡糖的适合的酶的实例包括合酶或连接酶或本领域已知的其它适合的酶,例如微生物来源或酵母来源的那些。
所述混合类型的寡糖还可以通过将寡糖从蛋白质物质分裂下来进行分离。
在制备混合类型的寡糖后,将它们优选地进行另外的纯化方法以去除肽能物质。
因此,将水性浆液进行层析或吸附技术,优选地在适合的pH加热和过滤或离心后进行所述技术。适合的吸附物质的实例是活性碳(activated coal)。
适合的混合寡糖的实例包括阿拉伯木聚糖,葡甘露聚糖和半乳甘露聚糖。尤其是包括超过1.5重量%的不同于两种主要单糖的单糖的那些对于本发明的目的将是适合的,例如阿拉伯木聚糖寡糖,其包括超过5重量%的葡糖苷酸。包含这样的寡糖是特别有利的,所述寡糖包括唾液酸和/或葡糖胺作为第三成分。特别优选包含超过3重量%唾液酸的混合类型的寡糖。
如果存在,优选不易消化的碳水化合物的量在由所述产品所提供的每100千卡约0.4到约3g不易消化的碳水化合物的范围内。在高度优选的产品中,含量是至少0.6g/100千卡。高度优选含量是2.0g/100千卡以下。
如果存在,优选至少60重量%的不易消化的碳水化合物由具有2-10范围内的聚合度的不易消化的碳水化合物形成。当溶解于水性液体中时,所述碳水化合物在它们的非粘性的特征方面是特别有利的。
如果存在,不易消化的碳水化合物优选地包括选自由半乳糖、果糖、糖醛酸、木糖、阿拉伯糖组成的组的至少两种不同的单糖单位。
通常地,食品包含可消化的碳水化合物组分。所述可消化的碳水化合物组分可以包括本领域已知适合用于食品中的一种或多种可消化的碳水化合物,例如选自可消化的多糖(例如,淀粉),可消化的单糖(例如,葡萄糖,果糖),和可消化的二糖(例如蔗糖)。尽管传统的配方在低变应性和易于消化的配方中排除了乳糖,并且通过应用如上给出的措施也已经获得了明显的积极作用,但是优选包含少量的乳糖,从而促进在胃肠道上部中的细菌生长,特别是共生体的那些细菌的生长。具体地,所述量是约0.05到约1.6g,优选地约0.1到约1g/100ml即用(液体)产品(或约0.2到约6.4g,优选地约0.4到约4g/100g干重)。
通常地,本发明的食品包括矿物组分。优选存在铁和铜的至少一种。矿物的存在可以对变态反应具有积极作用或有助于改善或避免其症状的发生。例如,预期Cu可以刺激能够中和导致炎性反应增加的自由基的酶的活性。
在一个实施方案中,铁和/或铜以包封盐(encapsulated salt)的形式存在。包封的盐可以在包装前,或在使用前溶解所述粉末产品前,适当地加入本发明的(喷雾干燥)的粉末产品中。
可存在一种或多种其它矿物,特别是选自由下列各项组成的组的一种或多种矿物:钠,钾,氯,钙,磷(作为磷酸盐),镁,锌,锰,碘,钼,硒和铬。
在所述低变应性和非变应性食品中,需要仔细考虑所述产品的缓冲能力,尤其是对于遭受营养不良和/或次佳消化过程的患者。使其尽可能的低是特别重要的。这通过选择约20到约36mg磷含量/100ml即用(液体)产品(约80到约104mg/100g干重)和优选地约22到约33mg磷含量/100ml即用(液体)产品和/或选择约30到约54mg钙水平/100ml(液体)产品(约120到约216mg/100g干重)和优选地约40到约50mg钙/100ml(液体)产品来实现。
还通过在所述产品中的有机酸的量来确定缓冲能力。鉴于此,柠檬酸的量少于0.5mg/100ml液体产品(或少于2.0mg/100g干重)。
鉴于此,乳清酸的量通常是5mg以下/100ml(液体)产品(或20mg/100g干重或更少),和优选地在约0.2到约4mg/100ml范围内。
尽管低缓冲能力是理想的,但是包含碳酸盐也是有利的,特别是在配方中加入碳酸氢盐,从而支持消化过程,特别是内分泌功能。碳酸盐,特别是以碳酸氢盐加入的量优选地应该在约0.05到约0.2g/100ml(或约0.2到约0.8g/100g干重)的范围内。
即用液体产品的摩尔渗透压浓度(osmolarity)足够低从而容许其易于通过胃传递并且预防回流问题也是重要的,所述问题在具有不良饮食行为的营养不良未成年人中是高度不理想的。因此,重量摩尔渗透压浓度(osmolality)应该在每升产品约260到约450,优选地约270到约370,和最优选地约280到约340mOsmol范围内。
一般存在一种或多种维生素。优选地,存在选自由下列各项组成的组的至少一种维生素:维生素A,维生素D,维生素C,维生素E,维生素K和维生素B族。具体而言,存在来自维生素B族的至少一种化合物,其选自硫胺、核黄素、烟酸、维生素B6、维生素B12、生物素、叶酸、泛酸(panthotenic acid)。维生素具有许多有利作用,如在本领域中所述。此外,认为维生素的存在可能有助于提高Th1/Th2比率。
在优选的本发明的产品中,存在至少一种有机酸,其能够结合水溶液中的游离的阳离子,优选地能够结合选自铜离子和铁离子的游离阳离子。因此,所述有机酸可以对长链多不饱和脂肪酸具有稳定作用。由此,特别地,脂肪酸的氧化可以被减少或甚至被防止。
优选地,存在选自柠檬酸和苹果酸的至少一种有机酸。
预期有机酸如柠檬酸或苹果酸有助于预防受试者对变应原的致敏过程。
此外,可以存在一种或多种其它的食物成分。具体地,可以存在一种或多种选自由胆碱和肌醇组成的组的成分。适合的浓度是本领域已知的。
本发明还涉及制备本发明所述的食品的方法,所述方法包括
-提供氨基酸组分、脂质组分和任选地不易消化的碳水化合物组分,基于干重,其分别包含少于0.01重量%,优选地少于0.001重量%的具有超过1000D的分子量的肽物质;
-组合所述组分和任选地一种或多种其它成分,由此形成所述产品。
如果加入一种或多种其它成分,具有超过1000的分子量的肽物质的含量应该是这样的,从而得到具有少于0.01重量%的肽物质的产物,所述肽物质具有超过1000的分子量。
用于制备食品的常规原材料(脂质来源,碳水化合物来源,氨基酸来源)来自天然来源并且典型地包含可以作为T细胞表位的肽/蛋白质(典型地具有超过1000D的分子量)。例如,鱼油(作为AA和/或DPA的来源)典型地包括肽物质。
根据本发明,要谨慎的是----特别是对于脂质组分、不易消化的碳水化合物组分(如果存在)和氨基酸组分----原材料用在不包含或仅包含少量所述肽和蛋白质的最终产品中。具体而言,在组合中,它们应该在食品中导致少于0.01重量%的具有超过1000D的分子量的肽能物质。
原则上,提供具有少于0.01重量%(或甚至少于0.001重量%)的肽物质的组分可以通过任何方式进行,所述肽物质具有大于1000的分子量。
例如,可以从组分中去除分子量超过1000的肽物质(包括可以用于获得所述组分的一种或多种酶),从而将所述含量减少到适合的浓度,所述去除例如通过层析、沉淀和/或过滤、特别是微量过滤和/或超滤进行,从而获得具有少于0.01重量%,优选地<0.001,更优选地<0.0001重量%的该种肽物质的产品。
本领域技术人员能够发现适合的方法。
一种或多种组分可以通过包括裂解细菌和去除或水解肽(包含蛋白质)的方法提供。
例如,不易消化的寡糖可以通过多糖的酸化水解或多糖的酶促水解获得。
作为多糖,例如,可以例如通过应用结晶、变性、分解、分离、沉淀或其组合来使用包含超过90%碳水化合物物质和少于1重量%的MW>1000道尔顿的肽物质的原材料。接着,该多糖可以用酶和/或酸进行处理。
如果需要,可以随后将酶和其它大的蛋白/肽去除以获得需要的纯度。
有利的是,不易消化的寡糖通过酸水解获得。由此,避免了潜在变应原性酶的应用。
从更小的糖,特别是从单糖,二糖和/或三糖(酶促)合成来合成不易消化的碳水化合物也是可能的。应该小心酶不能以太高的浓度保留在产品中。
包含游离脂肪酸、甘油单酯和/或甘油二酯的脂质组分可以从甘油三酯通过酸水解或酶促水解获得。在后一种情形中,所用的酶可以通过层析从所述组分中去除,例如通过将所述组分溶解在非极性溶剂中并通过极性柱洗脱所述级分来进行。
适合的氨基酸组分可以通过水解或合成来获得。氨基酸组分优选地是合成制备的。以合成方式提供级分的适合的方法是本领域已知的。如果使用酶,要小心将酶从产物中去除。
本发明还涉及减少受试者对变应原的敏感性的方法,其包括肠内施用本发明所述的食品给受试者,特别是未成年人,更特别地是年龄达10岁的未成年人。
本发明还涉及改善受试者的变态反应的方法,其包括肠内施用本发明所述的食品给受试者,特别是未成年人,更特别地是年龄达10岁的未成年人。
本发明还可以用于诊断变态反应。
特别地,本发明的食品可以用在诊断变态反应的方法中,所述方法包括肠内施用本发明的食品给受试者,特别是未成年人,更特别地是年龄达到10岁的未成年人。
在所述方法中,在足够的时间跨度,典型地从施用时刻起至少两小时内,给针对食物显示变态反应的受试者提供本发明的食品作为单一的营养物。
要小心使受试者不暴露于非食物变应原。
在所述阶段中,监测变态反应。如果存在的变态反应消失,可以推断出所述受试者之前摄取的食物导致变态反应。如果所述变态反应仍旧存在,最可能不是传统的食物(在食用本发明的食品前摄取的),而是环境来源的变应原导致了变态反应。
本发明还涉及脂质组合物,特别是天然来源的脂质组合物,其适合作为制备非变应原性食物组合物的成分,其包含基于总重的至少80重量%的一种或多种选自由下列各项组成的组的脂质:甘油三酯、甘油二酯、单酰甘油酯、磷脂、溶血磷脂、神经酰胺、鞘氨醇、神经节苷酯、游离脂肪酸、游离脂肪酸的盐、和游离脂肪酸的酯,所述脂质组合物包含花生四烯酸和二十二碳六烯酸的至少一种,所述脂质组合物具有基于干重的少于0.01重量%,优选地少于0.001重量%的T细胞表位含量。
特别地,所述组分可以选自磷脂组分、溶血磷脂组分、神经酰胺组分、酶促制备的甘油二酯组分和酶促制备的甘油单酯组分。
优选地,所述脂质组合物符合上述对于脂质组分所鉴定的一种或多种特征。
本发明还涉及难以消化的碳水化合物组合物,其优选是天然来源的,适合作为制备非变应原性食物组合物的成分,所述碳水化合物组合物包含基于碳水化合物组分的重量的至少80重量%的具有在3-20范围内的聚合度的寡糖,所述碳水化合物组合物具有基于干重的少于0.01重量%的T-细胞表位含量,优选地少于0.001重量%的T-细胞表位含量。优选地所述组合物符合对于上述碳水化合物组分鉴定的一种或多种特征。
本发明还涉及治疗患有乳糜泻(celiac disease)、囊性纤维化、短肠综合征、炎性肠病、囊性纤维化、癫痫的患者中或经历药物治疗、特别是非甾体抗炎药物、化疗剂、抗代谢药和抗生素的治疗人中的营养不良的方法,所述方法包括施用本发明所述的食品或本发明所述的难以消化的碳水化合物组合物,其中所述产品具有2.5-3.3千焦耳/毫升的或10.0到13.2千焦耳/克干重的能量密度。
本发明还涉及减少由于通过肠胃外途径施用物质引起的过敏性休克危险的方法,所述方法包括在施用所述物质的时刻前至少1小时施用本发明所述的食品。
本发明还涉及影响内源量的T辅助细胞和/或T调节细胞、激活Toll样受体、或组胺或γ-干扰素的血浆水平的方法,所述方法包括施用本发明所述的食品或本发明所述的难以消化的碳水化合物组合物。
本发明还涉及治疗尿布疹、过敏性皮肤反应、正常睡眠行为障碍、在变应性未成年人或具有特应性体质的未成年人中的过分的哭闹,或减少其发生的危险的方法,所述方法包括施用本发明所述的食品或本发明所述的难以消化的碳水化合物组合物。
实施例:
实施例1:非变应性食品配方
非变应性产品每100ml(或15.4g粉末)包含
根据规定和推荐的微量成分
在所述食物组合物中,可以加入来自下列组的纤维:
其至少50%包含三种单糖。
实施例2用于幼龄癫痫患者的营养配方
能量密度:0.6-0.77千卡/ml或2.52-3.24千焦耳/毫升
脂质:5.5到7g/100ml即用配制方
脂肪酸分布:
棕榈酸:15-40,优选地22-38,最优选地26-36重量%的脂肪酸和任选地但是优选地下列各项中的一种或多种:DHA:0.16-8重量%,AA:0.4-8重量%,AA/DHA=1-5:1和LA(C18:2)/DHA=1-47:1,并且其中脂质组分任选地但是优选地包含多于8重量%的磷脂、溶血磷脂、神经酰胺、鞘氨醇(sphingosides)、糖脂或胆固醇或其等价物。
实施例3:本发明所述的产品的脂质组分的典型含量
脂质组分提供0,7g DHA和0,7g AA/100g脂肪酸,并且包括:
每95g甘油三酯:
磷脂 0.5-4g
胆固醇 0.5-1.5g和
糖脂 0.1-2克
实施例4:适合用在抗变应性配方中的蛋白质组分
蛋白质等价物
合成的氨基酸
天然的氨基酸选自:Arg,Thr,Trp,Met,Ala,Trp,Cys,Leu,Ile,Val,Phe,Tyr,其以D或L两种形式存在。
实施例5:存在于本发明所述的抗-变应性配方中的阴离子组分
每100ml即用配方:
Claims (25)
1.食品,其包含
-氨基酸组分,其包含选自由氨基酸和聚合度为7以下的肽组成的组的至少一种成分;
-脂质组分,其包含选自由花生四烯酸和二十二碳六烯酸组成的组的至少一种脂肪酸,并且所述脂质组分包含大于0.1重量%的胆固醇;
-细菌细胞壁的片段;
-选自由寡聚半乳糖、寡聚果糖、寡聚木糖、寡聚甘露糖、寡聚半乳糖醛酸和寡聚阿拉伯糖组成的组的至少一种寡糖;
所述食品具有一定含量的具有1000道尔顿以上的分子量的肽,所述含量为基于干重少于0.01重量%。
2.根据权利要求1的食品,其中至少80重量%的脂质组分由选自由下列各项组成的组的一种或多种脂质提供:磷脂、神经酰胺、鞘氨醇、神经节苷酯、游离脂肪酸、游离脂肪酸的盐和游离脂肪酸的酯。
3.根据权利要求1的食品,其中所述花生四烯酸含量是0.025-6g/l00g脂肪酸。
4.根据权利要求1的食品,其中所述二十二碳六烯酸含量是0.015-1.5g/100g脂肪酸。
5.根据权利要求1的食品,所述食品具有的亚油酸与二十碳五烯酸、花生四烯酸和二十二碳六烯酸的总和的比率是47以下。
6.根据权利要求1的食品,其中所述氨基酸组分包含少于0.001重量%的具有8以上的聚合度的肽。
7.根据权利要求1的食品,其中所述氨基酸组分提供1.0-6.9g精氨酸,5.5-12g苏氨酸和2.2-6.0g色氨酸/100g氨基酸。
8.根据权利要求1的食品,其中分子量为1000道尔顿以上的肽的含量少于0.0001重量%。
9.根据权利要求1的食品,所述食品具有基于干重少于0.01重量%的T细胞表位含量。
10.根据权利要求1的食品,其中所述食品是干的。
11.根据权利要求1的食品,其中所述氨基酸组分提供8-16能量%,所述脂质组分提供38-52能量%和其中38-47能量%由碳水化合物组分提供。
12.根据权利要求1的食品,其中所述片段是选自由乳杆菌(Lactobacilli)和双歧杆菌属(Bifidobacteriae)组成的组的细菌的片段。
13.根据权利要求1的食品,所述食品包含细菌。
14.根据权利要求13的食品,其中所述细菌选自由乳杆菌和双歧杆菌属组成的组。
15.根据权利要求13的食品,其中所述细菌的量是每100ml即用产品108个细菌到1011个细菌,或基于干重:每100g产品4x108到4x1011个细菌。
16.根据权利要求1的食品,其中具有1000道尔顿以上的分子量的肽包括蛋白质。
17.根据权利要求6的食品,其中具有8以上的聚合度的肽包括蛋白质。
18.制备权利要求1-17中任一项的食品的方法,所述方法包括:
-提供氨基酸组分、脂质组分、和难以消化的碳水化合物组分,所述难以消化的碳水化合物组分包含选自由寡聚半乳糖、寡聚果糖、寡聚木糖、寡聚甘露糖、寡聚半乳糖醛酸和寡聚阿拉伯糖组成的组的至少一种寡糖,所述组分中的每一种包含少于0.01重量%的具有大于1000D的分子量的肽物质,
-组合所述组分,由此形成所述食品。
19.根据权利要求1-17中任一项的食品在制备用于减少受试者对变应原的敏感性的组合物中的应用,其通过给所述受试者肠内施用所述食品来减少。
20.根据权利要求19的食品的应用,其中所述受试者是未成年人。
21.根据权利要求1-17中任一项的食品在制备用于改善受试者的变态反应的组合物中的应用,其包括将所述食品肠内施用于所述受试者。
22.根据权利要求21的食品的应用,其中所述受试者是未成年人。
23.根据权利要求1-17中任一项的食品在制备用于诊断受试者的变态反应的组合物中的应用。
24.根据权利要求23的食品的应用,其中所述受试者是未成年人。
25.根据权利要求1-17中任一项的食品在制备用于治疗尿布疹、过敏性皮肤反应、正常睡眠行为的障碍、在变应性未成年人或具有特应性体质的未成年人中的过分哭闹或减少其发生的危险的组合物中的应用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82146106P | 2006-08-04 | 2006-08-04 | |
US60/821,461 | 2006-08-04 | ||
CN200780036351.6A CN101522055B (zh) | 2006-08-04 | 2007-08-03 | 非变应原性的成分和食品 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780036351.6A Division CN101522055B (zh) | 2006-08-04 | 2007-08-03 | 非变应原性的成分和食品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104012838A CN104012838A (zh) | 2014-09-03 |
CN104012838B true CN104012838B (zh) | 2017-09-19 |
Family
ID=38657076
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780053668A Pending CN101795579A (zh) | 2006-08-04 | 2007-07-05 | 无蛋白配方 |
CN201410047278.4A Active CN104012838B (zh) | 2006-08-04 | 2007-08-03 | 非变应原性的成分和食品 |
CN200780036351.6A Active CN101522055B (zh) | 2006-08-04 | 2007-08-03 | 非变应原性的成分和食品 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780053668A Pending CN101795579A (zh) | 2006-08-04 | 2007-07-05 | 无蛋白配方 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780036351.6A Active CN101522055B (zh) | 2006-08-04 | 2007-08-03 | 非变应原性的成分和食品 |
Country Status (15)
Country | Link |
---|---|
US (5) | US8691213B2 (zh) |
EP (4) | EP2164349B1 (zh) |
KR (1) | KR20090045930A (zh) |
CN (3) | CN101795579A (zh) |
AU (2) | AU2007280272A1 (zh) |
BR (2) | BRPI0721827B8 (zh) |
DK (2) | DK2164349T3 (zh) |
ES (2) | ES2525223T3 (zh) |
IL (1) | IL196786A0 (zh) |
MX (1) | MX2010000172A (zh) |
PL (2) | PL2164349T3 (zh) |
PT (2) | PT2164349E (zh) |
RU (1) | RU2436414C2 (zh) |
WO (2) | WO2008015374A2 (zh) |
ZA (1) | ZA200900817B (zh) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080126195A1 (en) | 2004-07-22 | 2008-05-29 | Ritter Andrew J | Methods and Compositions for Treating Lactose Intolerance |
DK2164349T3 (en) | 2006-08-04 | 2014-12-15 | Shs Int Ltd | protein-FORMULA |
US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
WO2009058799A1 (en) * | 2007-11-01 | 2009-05-07 | Wake Forest University School Of Medicine | Compositions and methods for prevention and treatment of mammalian diseases |
US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
GB0805360D0 (en) * | 2008-03-25 | 2008-04-30 | Univ Leuven Kath | Arabinoxylan oligosaccharide preparation |
EP2143340A1 (en) | 2008-07-07 | 2010-01-13 | Nestec S.A. | A nutritional composition with free amino acids and structured lipids |
CN107320480A (zh) | 2009-02-24 | 2017-11-07 | 里特制药股份有限公司 | 益生素制剂和使用方法 |
ES2622091T5 (es) * | 2009-08-18 | 2020-10-19 | Cosucra Groupe Warcoing Sa | Composiciones que contienen mezclas de fibras fermentables |
WO2011021926A1 (en) * | 2009-08-21 | 2011-02-24 | N.V. Nutricia | Regulating the amino acid pool used for the acute-phase protein synthesis |
ES2524067T3 (es) * | 2009-12-04 | 2014-12-03 | Mjn U.S. Holdings Llc | Formulación nutricional que comprende un hidrolizado que contiene péptidos de leche de vaca y/o péptidos derivados del mismo para la inducción de tolerancia |
EP2563372A4 (en) | 2010-04-28 | 2013-10-02 | Ritter Pharmaceuticals Inc | PREBIOTIC FORMULATIONS AND METHODS OF USE |
WO2011149335A1 (en) * | 2010-05-25 | 2011-12-01 | N.V. Nutricia | Immune imprinting nutritional composition |
WO2011150949A1 (en) * | 2010-06-04 | 2011-12-08 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
EP3508075B1 (en) * | 2010-06-04 | 2022-10-26 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
US20130116174A1 (en) * | 2010-07-11 | 2013-05-09 | The Board Of Trustees Of The University Of Arkansas | Compositions and methods for increasing poultry hatchability and early performance |
CN101940238B (zh) * | 2010-08-13 | 2013-09-11 | 广东润科生物工程有限公司 | 一种营养保健食用油及其制备方法和其包装结构 |
CN101978841B (zh) * | 2010-08-31 | 2013-04-10 | 浙江贝因美科工贸股份有限公司 | 一种抗蛋白过敏及营养婴儿配方奶粉 |
BR112013006044B1 (pt) | 2010-09-24 | 2022-03-29 | University Of Florida Research Foundation, Inc | Composição terapêutica para administração enteral compreendendo como aminoácidos livres, serina e valina, bem como embalagem contendo a dita composição |
EP2465508A1 (en) * | 2010-11-23 | 2012-06-20 | Nestec S.A. | Composition comprising hydrolysed proteins and oligosaccharides for treating skin diseases |
WO2012092089A1 (en) | 2010-12-29 | 2012-07-05 | Abbott Laboratories | Nutritional products including monoglycerides and fatty acids |
NZ612472A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
CA2822497C (en) | 2010-12-31 | 2020-07-28 | Abbott Laboratories | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
SG191392A1 (en) | 2010-12-31 | 2013-08-30 | Abbott Lab | Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides |
MX355424B (es) | 2010-12-31 | 2018-04-18 | Abbott Lab | Oligosacáridos de leche humana para modular la inflamación. |
US8703737B2 (en) | 2010-12-31 | 2014-04-22 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
NZ612455A (en) | 2010-12-31 | 2015-02-27 | Abbott Lab | Human milk oligosaccharides to promote growth of beneficial bacteria |
US8802650B2 (en) | 2010-12-31 | 2014-08-12 | Abbott Laboratories | Methods of using human milk oligosaccharides for improving airway respiratory health |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
MY169326A (en) | 2011-08-29 | 2019-03-21 | Abbott Lab | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
WO2013051928A1 (en) | 2011-10-06 | 2013-04-11 | N.V. Nutricia | Treatment of eosinophilic esophagitis |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
WO2013133691A1 (en) * | 2012-03-09 | 2013-09-12 | N.V. Nutricia | Liquid nutritional composition comprising free amino acids |
CN110292592A (zh) | 2012-09-21 | 2019-10-01 | 雀巢产品有限公司 | 植物酚及其在治疗或预防嗜酸性食管炎中的用途 |
BR112015009579B1 (pt) * | 2012-11-02 | 2020-04-28 | Nutricia Nv | uso de glutamina, bifidobacterium breve e pelo menos um oligossacarídeo não digerível, e composição nutricional |
US11179427B2 (en) | 2013-01-21 | 2021-11-23 | Eth Zurich | Baby food composition comprising viable propionic acid-producing bacteria |
WO2014164736A1 (en) * | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
WO2014200334A1 (en) * | 2013-06-14 | 2014-12-18 | N.V. Nutricia | Synbiotic composition for treatment of infections in allergic patients |
WO2015154259A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154251A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them. |
WO2015154254A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and nutritional systems comprising them |
WO2015154257A1 (en) * | 2014-04-09 | 2015-10-15 | Nestle (China) Ltd. | Gender specific synthetic nutritional compositions and, nutritional systems comprising them |
PT3193901T (pt) | 2014-12-23 | 2018-06-29 | 4D Pharma Res Ltd | Polipéptido de pirina e modulação imunitária |
EP3065748B1 (en) | 2014-12-23 | 2017-11-22 | 4D Pharma Research Limited | A bacteroides thetaiotaomicron strain and its use in reducing inflammation |
WO2016148562A1 (en) * | 2015-03-18 | 2016-09-22 | N.V. Nutricia | Method for inducing oral tolerance via administration of beta-lactoglobulin derived peptide in combination with probiotic |
WO2016183535A1 (en) | 2015-05-14 | 2016-11-17 | University Of Puerto Rico | Methods for restoring microbiota of newborns |
PE20180267A1 (es) | 2015-06-15 | 2018-02-06 | 4D Pharma Res Ltd | Composiciones que comprenden cepas bacterianas |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
ES2753779T3 (es) | 2015-06-15 | 2020-04-14 | 4D Pharma Res Ltd | Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
HUE046770T2 (hu) | 2015-06-15 | 2020-03-30 | 4D Pharma Res Ltd | Baktériumtörzseket tartalmazó készítmények |
WO2017058016A1 (en) * | 2015-10-02 | 2017-04-06 | N.V. Nutricia | Glycine for use in tolerance induction in allergic patients |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
ES2662617T3 (es) | 2015-11-20 | 2018-04-09 | 4D Pharma Research Limited | Composiciones que comprenden cepas bacterianas |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CA3004976A1 (en) * | 2015-12-04 | 2017-06-08 | Nestec S.A. | Cocoa polyphenols and soluble dietary fiber for use in the treatment or prevention disorders associated with an above-normal number of granulocytes in a tissue |
US11564667B2 (en) | 2015-12-28 | 2023-01-31 | New York University | Device and method of restoring microbiota of newborns |
CN108697141A (zh) * | 2015-12-29 | 2018-10-23 | N·V·努特里奇亚 | 含有不可消化寡糖和非复制型产乳酸细菌的营养配方物 |
CN107041546A (zh) * | 2016-02-05 | 2017-08-15 | 上海他普亚贸易有限公司 | 一种氨基酸配方粉及其制备方法 |
AU2017226831B2 (en) | 2016-03-04 | 2018-10-04 | 4D Pharma Plc | Compositions comprising bacterial Blautia strains for treating visceral hypersensitivity |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
CA2973679A1 (en) * | 2016-07-15 | 2018-01-15 | Kay Jay, Llc | Composition and method for altering hair pigmentation |
BR112019006742A2 (pt) * | 2016-10-04 | 2019-09-03 | Entrinsic Health Solutions Inc | composições de aminoácido e usos das mesmas |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
TW201907929A (zh) | 2017-05-22 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
TW201919668A (zh) | 2017-06-14 | 2019-06-01 | 英商4D製藥研究有限公司 | 包含細菌品系之組成物 |
EP3638271B1 (en) | 2017-06-14 | 2020-10-14 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
US20210259979A1 (en) * | 2018-07-24 | 2021-08-26 | Clover Corporation Limited | Protein encapsulation of nutritional and pharmaceutical compositions |
CN112244097A (zh) * | 2020-10-19 | 2021-01-22 | 湖南欧比佳营养食品有限公司 | 一种含有氨基酸及无乳糖的配方奶粉及其制备方法 |
US20240009216A1 (en) | 2020-11-10 | 2024-01-11 | Societe Des Produits Nestle S.A. | Nutritional composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293571A (en) * | 1979-03-09 | 1981-10-06 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for the preparation of a purified protein hydrolysate |
CN1358500A (zh) * | 2000-12-13 | 2002-07-17 | 诺瓦提斯营养股份公司 | 含有游离氨基酸和核苷酸的婴儿制剂 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5922766A (en) * | 1997-07-02 | 1999-07-13 | Acosta; Phyllis J. B. | Palatable elemental medical food |
US6077558A (en) | 1998-12-23 | 2000-06-20 | Bristol-Myers Squibb Company | Elemental nutritional products |
MY129566A (en) * | 1999-01-19 | 2007-04-30 | Nestle Sa | A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance |
DE10221403A1 (de) * | 2002-05-14 | 2003-12-04 | Kyberg Pharma Vertriebs Gmbh & | Diätetische und pharmazeutische Zusammensetzungen, ihre Herstellung und ihre Verwendung |
JP4740866B2 (ja) * | 2003-10-24 | 2011-08-03 | ナムローゼ フェンノートシャップ ニュートリシア | 乳児向けシンバイオティック組成物 |
US8557794B2 (en) | 2003-10-24 | 2013-10-15 | N.V. Nutricia | Immunemodulating oligosaccharides |
EP1597978A1 (en) * | 2004-05-17 | 2005-11-23 | Nutricia N.V. | Synergism of GOS and polyfructose |
US8252769B2 (en) * | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
EP1634599A1 (en) | 2004-08-20 | 2006-03-15 | N.V. Nutricia | Iimmune stimulatory infant nutrition |
RU2282995C2 (ru) | 2004-12-17 | 2006-09-10 | Открытое акционерное общество "Лианозовский молочный комбинат" | Пищевой продукт |
TW200637908A (en) | 2005-01-04 | 2006-11-01 | Calpis Co Ltd | Method for preparation of lactic acid bacterium having anti-allergic activity |
DK1855550T3 (da) * | 2005-02-28 | 2012-01-16 | Nutricia Nv | Næringspræparat med probiotika |
EP1714660A1 (en) * | 2005-04-21 | 2006-10-25 | N.V. Nutricia | Uronic acid and probiotics |
EP1963254A2 (en) | 2005-09-21 | 2008-09-03 | Torrent Pharmaceuticals Ltd | Process for the preparation of lercanidipine and amorphous form of lercanidipine hydrochloride |
WO2007054989A1 (en) * | 2005-10-11 | 2007-05-18 | Anidral S.R.L. | Method for the preparation of anallergic probiotic bacterial cultures and related use |
US20070114476A1 (en) * | 2005-11-04 | 2007-05-24 | Williams Christopher P | Low radiocarbon nucleotide and amino acid dietary supplements |
DK2164349T3 (en) | 2006-08-04 | 2014-12-15 | Shs Int Ltd | protein-FORMULA |
-
2007
- 2007-07-05 DK DK07766165.0T patent/DK2164349T3/en active
- 2007-07-05 US US12/666,845 patent/US8691213B2/en active Active
- 2007-07-05 MX MX2010000172A patent/MX2010000172A/es not_active Application Discontinuation
- 2007-07-05 PL PL07766165T patent/PL2164349T3/pl unknown
- 2007-07-05 ES ES07766165.0T patent/ES2525223T3/es active Active
- 2007-07-05 CN CN200780053668A patent/CN101795579A/zh active Pending
- 2007-07-05 EP EP07766165.0A patent/EP2164349B1/en active Active
- 2007-07-05 BR BRPI0721827A patent/BRPI0721827B8/pt active IP Right Grant
- 2007-07-05 WO PCT/GB2007/002520 patent/WO2008015374A2/en active Search and Examination
- 2007-07-05 EP EP14181628.0A patent/EP2845496A1/en not_active Ceased
- 2007-07-05 AU AU2007280272A patent/AU2007280272A1/en not_active Abandoned
- 2007-07-05 PT PT77661650T patent/PT2164349E/pt unknown
- 2007-07-19 US US11/779,975 patent/US20080031814A1/en not_active Abandoned
- 2007-08-03 CN CN201410047278.4A patent/CN104012838B/zh active Active
- 2007-08-03 ES ES07808526.3T patent/ES2605177T3/es active Active
- 2007-08-03 PT PT78085263T patent/PT2061346T/pt unknown
- 2007-08-03 BR BRPI0715335-0A patent/BRPI0715335A2/pt not_active Application Discontinuation
- 2007-08-03 CN CN200780036351.6A patent/CN101522055B/zh active Active
- 2007-08-03 AU AU2007279448A patent/AU2007279448A1/en not_active Abandoned
- 2007-08-03 WO PCT/NL2007/050393 patent/WO2008016306A1/en active Application Filing
- 2007-08-03 DK DK07808526.3T patent/DK2061346T3/da active
- 2007-08-03 EP EP07808526.3A patent/EP2061346B1/en active Active
- 2007-08-03 EP EP16177232.2A patent/EP3114943B1/en not_active Revoked
- 2007-08-03 RU RU2009107681/13A patent/RU2436414C2/ru active
- 2007-08-03 PL PL07808526T patent/PL2061346T3/pl unknown
- 2007-08-03 KR KR1020097004430A patent/KR20090045930A/ko not_active Application Discontinuation
-
2009
- 2009-01-29 IL IL196786A patent/IL196786A0/en unknown
- 2009-02-03 ZA ZA200900817A patent/ZA200900817B/xx unknown
- 2009-02-03 US US12/364,717 patent/US9427011B2/en active Active
-
2014
- 2014-03-12 US US14/206,173 patent/US20140193542A1/en not_active Abandoned
-
2016
- 2016-08-02 US US15/226,107 patent/US20160338398A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4293571A (en) * | 1979-03-09 | 1981-10-06 | Societe D'assistance Technique Pour Produits Nestle S.A. | Process for the preparation of a purified protein hydrolysate |
CN1358500A (zh) * | 2000-12-13 | 2002-07-17 | 诺瓦提斯营养股份公司 | 含有游离氨基酸和核苷酸的婴儿制剂 |
Non-Patent Citations (1)
Title |
---|
The importance of peptide lengths in hypoallergenic infant formulae;Andre D.Siemensma,et al.;《Trends in Food Science & Technology》;19930131;第4卷;第17页第1栏第1-2段,第18页第2栏第2-3段,第20页第2栏第2段以及图2a * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104012838B (zh) | 非变应原性的成分和食品 | |
EP2658405B1 (en) | Nutritional products including a fat system including free fatty acids | |
KR102186932B1 (ko) | 식이 지방산 수요를 공급하기 위한 방법들, 조성물들 및 디바이스들 | |
TW201729693A (zh) | 含有膳食性丁酸鹽之營養組成物和彼之用途 | |
EP2865278A1 (en) | Fat binder obtained from biomass resulting from beer production | |
EP3897608B1 (en) | Dietary butyrate for treating or preventing an allergic disorder | |
WO2023099750A1 (en) | Nutritional composition for improving infant microbiota | |
RU2316220C1 (ru) | Продукт энтерального питания "нутриэн элементаль" | |
TW201233331A (en) | Nutritional products including monoglycerides and fatty acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |